Anti-platelet + Pembro for H&N Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 6, 2018

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2024

Conditions

Head and Neck Cancer

Interventions

DRUG

Pembrolizumab

200mg intravenous (IV) over 30 minutes

DRUG

Clopidogrel

75mg/day oral

DRUG

acetylsalicylic acid

81mg/day oral

Trial Locations (1)

Medical University of South Carolina, Charleston

All Listed Sponsors

lead

Medical University of South Carolina

OTHER

NCT03245489 - Anti-platelet + Pembro for H&N Tumors | Biotech Hunter | Biotech Hunter